• ALX Oncology named Scott Garland chairman, replacing co-founder Corey Goodman, who stepped down as chairman and board member.
• Garland has served on the board since November 2022, bringing more than 30 years of biopharmaceutical commercial and operational experience.
• Michael Listgarten joined as general counsel, adding experience in complex transactions, governance, and public-company matters.
• Changes take effect immediately.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300800PRIMZONEFULLFEED9754304) on June 30, 2026, and is solely responsible for the information contained therein.